Depomed on Wednesday announced that the Food and Drug Administration has accepted for filing a new drug application from Mallinckrodt for MNK-155.
Depomed has launched a new drug for breakthrough pain in cancer patients, the company said Monday.
Drug maker Depomed has sold its interests in royalty and milestone payments for several Type 2 diabetes drugs to PDL BioPharma, Depomed said.
Drug maker Depomed has expanded the geographic scope of a license agreement it has with Merck for diabetes drugs, the company said.
The Food and Drug Administration has accepted a regulatory approval application for a drug for hot flashes from Depomed, the drug maker said.
A drug maker is suing the Food and Drug Administration to force the agency to give a special designation to one of its drugs.